Please assess the completion status of the following clinical trial:

Trial Title: COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have not been treated with a glaucoma medication within 6 weeks prior to study participation after diagnosis with primary open-angle glaucoma~* Patients with primary open-angle glaucoma based on gonioscopy~* Patients with normal tension glaucoma diagnosed based on accompanying optic disc cupping and reappearance of visual field defect corresponding to retinal nerve fiber layer defect.~* Subjects with \< 22 mm Hg of diurnal IOP measured using Goldmann applanation tonometer (every two hours between 9 a.m. and 5 p.m.)~Exclusion Criteria:~* Patients with another type of glaucoma but primary open-angle glaucoma~* Patients treated with other glaucoma medications within 6 weeks prior to study participation~* Patients with a history of chronic ocular inflammation or recurrent ocular inflammation~* Patients using contact lenses~* Patients who are allergic to timolol or dorzolamide~* Patients with a history of any of the following COSOPT (timolol/dorzolamide combination) contraindications:~  * Reactive airway diseases~ * Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock~ * Severe renal impairment~* Patients with a history of significant ocular trauma or intraocular surgery within 6 months before participating the study, or intraocular laser surgery within 3 months before the participating the study~* Patients with a history of a corneal disease~* Patients who are using steroid or used the drug for more than 2 weeks within 12 months before participating the study~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Timolol/Dorzolamide (Type: EXPERIMENTAL): Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).